Figure 5.
IgA antibodies are not critical in cross-protection. IgA KO mice and BALB/c mice were vaccinated thrice i.n. with PBS (A,E), non-adjuvanted WIV (B,F), WIV+CAF-09 (C,G) or WIV+CTA1-3M2e-DD (D, H) followed by heterosubtypic challenge. The mice were followed for survival (A–D) and development of clinical symptoms (E–H) for a period of 14 days. IgA KO mice are represented by dashed lines with open symbols while BALB/c wt mice are represented by solid lines with filled symbols. Dotted lines indicate humane endpoint.